Gilead Sciences Stock Surges Over 5% as 2025 Net Profit Skyrockets Nearly 17-Fold

Stock News02-11 23:31

Shares of Gilead Sciences (GILD.US) climbed more than 5% on Wednesday, reaching $155.54 and setting a new all-time high. The company's latest financial report revealed full-year 2025 revenue of $29.443 billion, a 2.4% increase compared to the previous year. Net profit attributable to the listed company surged to $8.51 billion, representing a staggering increase of approximately 16.73 times year-over-year. Non-GAAP diluted earnings per share were $8.15, a substantial 77% rise from the prior year. Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences, stated that the past year was highly productive for the company. He highlighted the successful launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, alongside the continued growth of Biktarvy and Descovy, which have established a solid foundation for the company's growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment